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Objectives:  Combined heart-kidney transplantation with allografts from the same
donor has been long proved to be a feasible approach for selected patients with
coexisting end-stage cardiomyopathy and renal disease. The purpose of this retro-
spective study is to analyze our long-term results and compare these results with
heart-only transplantation over a 7-year period.
Methods:  Between June 1992 and April 1999, 10 patients underwent combined
heart-kidney transplantation at Cedars-Sinai Medical Center. They were all men
from 44 to 70 years old (mean age, 59 ± 8.3 years) who had a mean left ventricular
ejection fraction of 19.4% ± 5.0% (range, 9%-25%) and a mean creatinine clear-
ance of 25.4 mL/min (range, 10-39 mL/min). Four patients underwent pretrans-
plantation dialysis.
Results:  There was no operative mortality. The actuarial survival at 1, 2, and 5 years
was 100%, 88% ± 11.7%, and 55% ± 20.1%, respectively. By comparison, the oper-
ative mortality of 169 patients who underwent heart-only transplantation during the
same time interval was 2.4%, with an actuarial survival at 1, 2, and 5 years of 92%
± 2.1%, 84% ± 2.8%, and 71% ± 3.9%, respectively (P = .37). Eight patients
showed no evidence of significant (≥1B) cardiac allograft rejection postoperatively,
and the actuarial freedom from rejection at 30 days, 1 year, and 2 years was 90% ±
9%, 80% ± 13%, and 80% ± 13%, respectively. Renal allograft survival was 90%
at 1 and 2 years.
Conclusions:  Combined heart-kidney transplantation yields satisfactory long-term
results similar to those for heart-only transplantation, with a low incidence of car-
diac allograft rejection and renal allograft survival when both allografts are from the
same donor. This approach effectively expands the selection criteria for heart-only
and kidney-only transplantation in potential candidates with coexisting end-stage
cardiac and renal disease.
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Combined heart-kidney transplantation,although infrequently performed, hasbecome an accepted therapeutic option forpatients with end-stage heart disease associ-ated with severely impaired renal function.Experience with this combined approach
has shown that the presence of abnormal renal function does
not preclude heart transplantation, provided there are no
signs of other organ failure. Conversely, the presence of
severely impaired cardiac function in patients with end-
stage renal disease no longer presents a contraindication for
kidney transplantation if they are otherwise good candi-
dates.
Our initial experience with this cohort of patients was
reported in 1994 and included 3 patients who underwent
combined heart-kidney transplantation with allografts from
the same donor.1 Encouraged by our results, we have pur-
sued this approach in 10 patients who form the basis of this
report. This retrospective analysis focuses on the lessons
learned, particularly regarding patient and donor selection,
postoperative management, and surveillance, as well as
long-term patient and allograft outcome.
Materials and Methods
Between June 1992 and April 1999, 169 patients underwent heart
transplantation, 393 patients underwent kidney transplantation,
and an additional 10 patients underwent combined heart-kidney
transplantation at Cedars-Sinai Medical Center. The preoperative
characteristics are shown in Table 1. The cause of renal disease is
shown in Table 2, and the preoperative renal function and dialysis
status are shown in Table 3. Only 1 patient was undergoing dialy-
sis at the time of listing for transplantation (having undergone an
unsuccessful kidney transplant previously), and 3 additional
patients began dialysis while awaiting transplantation. Donor heart
characteristics are presented in Table 4, and intraoperative charac-
teristics are provided in Table 5.
Our criteria for renal transplantation along with cardiac trans-
plantation included a creatinine clearance of less than 40 mL/min
and a serum creatinine level of more than 2.0 mg/dL, despite
hemodynamic optimization with intravenous inotropic and
vasodilator agents measured on at least 2 occasions.
All patients underwent combined heart-kidney transplantation
with a staged approach; namely, the renal allograft implantation
was delayed to a second operative procedure a few hours after car-
diac transplantation to allow for hemodynamic stabilization and
correction of coagulation abnormalities if present. Although no
post-transplantation renal biopsies were performed to diagnose
acute rejection episodes, the function of the transplanted kidney in
the early postoperative period was followed by serial renal duplex
scans measuring parenchymal blood flow for resistance index,
renal arterial and venous flow signal, and color Doppler perfusion
to assess allograft size.
Data were summarized by means of frequencies and percent-
ages for categorical variables and means and standard deviations
for continuous variables. Survival probabilities were calculated
with the actuarial method of estimation. The life-table method by
means of Kaplan-Meier analysis was used to construct survival
curves.
Immunosuppressive therapy consisted of OKT3 induction ther-
apy (5 mg administered intravenously daily) maintained for 7 days
in the first 6 patients. The remaining 4 patients received antithy-
mocyte globulin (15 mg/kg daily adjusted for white blood cell and
platelet counts) for 7 days. Maintenance immunosuppressive ther-
apy consisted of cyclosporine (INN: ciclosporin; 5 mg · kd–1 · d–1,
for a level of 200 to 400 ng/mL, as measured with a monoclonal
fluorescence polarization immunoassay within the first 12 weeks
after transplantation and for a level of 120 to 200 ng/mL thereafter,
started postoperatively once the serum creatinine level was less
than 2.0 mg/dL); azathioprine (4 mg/kg preoperatively and 2 mg ·
kd–1 · d–1 postoperatively adjusted to the patient’s white blood cell
and platelet count) later switched to mycophenolate mofetil (1000
mg twice daily) for all patients as of January 1997; and steroids
(methylprednisolone sodium succinate, 1 g at removal of aortic
cross-clamp intraoperatively and then 125 mg intravenously every
8 hours for 3 doses postoperatively, followed by prednisone, 0.25
mg · kg–1 · d–1, during OKT3 or antithymocyte globulin therapy,
increased to 0.5 mg · kg–1 · d–1, and then tapered off in the subse-
quent 3 to 8 months). Endomyocardial biopsies were performed
according to our surveillance protocol or when acute cardiac rejec-
tion was clinically suspected. Cardiac rejection episodes were
treated if greater than 1B, according to the classification of the
International Society for Heart and Lung Transplantation. Renal
allograft rejection was suspected by means of indirect serum bio-
chemical measurements of renal function and by means of Doppler
ultrasonographic resistance index–perfusion scan techniques and
treated accordingly.
Results
The 30-day operative mortality was 0%, and actuarial sur-
vival at 1, 2, and 5 years was 100%, 88% ± 11.7%, and 55%
± 20.1%, respectively. By comparison, the operative mortal-
ity of 169 patients who underwent heart transplantation in
our institution during the same period of time was 2.4%,
with an actuarial survival at 1, 2, and 5 years of 92% ±
2.1%, 84% ± 2.8%, and 71% ± 3.9%, respectively (P = .37,
Figure 1). Renal allograft survival was 90% at 1 and 2 years.
However, no statistically significant prediction of the 5-year
renal allograft survival could be made because of the small
number of patients with a 5-year follow-up (Figure 1).
Postoperative renal function is shown in Table 6.
Diuresis caused by the well-functioning kidney allograft
was observed soon after transplantation in all patients,
which avoided the need for post-transplantation dialysis.
The serum creatinine level fell below 2.0 mg/dL in all
patients within 7 to 10 days after transplantation. Renal
complications in the post-transplant period included one
episode of acute tubular necrosis caused by cyclosporine
toxicity at 30 days that resolved without the need for dialy-
sis and without observed improvement in the patient’s
native renal function. A second patient had an episode of
severe acute rejection with renal parenchymal infarct that
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required allograft nephrectomy 30 days after transplanta-
tion. (The patient’s native renal function only partially
recovered after transplantation but eventually deteriorated
and required dialysis 1 year later.) In contrast, of the 169
patients who underwent heart-only transplantation during
the same study time interval and who had a creatinine clear-
ance greater than 40 mL/min and a serum creatinine level
below 2.0 mg/dL, only 1 patient required renal transplanta-
tion (living related) for deteriorating renal function 5 years
after heart transplantation. In addition, 2 other similar
patients were placed on permanent dialysis 4 and 5 years
after heart transplantation, respectively, and are awaiting
kidney transplantation. However, an additional 14 patients
with similar preoperative characteristics have demonstrated
deteriorating renal function with a serum creatinine level
between 2.5 and 3.5 mg/dL in the late postoperative period.
The actuarial freedom from cardiac allograft rejection
(International Society for Heart Lung Transplantation clas-
sification, ≥1B) at 30 days, 1 year, and 2 years was 90% ±
9%, 80% ± 13%, and 80% ± 13%, respectively. Only 2
patients showed a single episode of cardiac rejection (≥1B)
on endomyocardial biopsy, one graded 3A at 30 days and
another graded 3B at 60 days, which resolved with pulsed-
steroid therapy. Three patients died in the follow-up period:
one patient died of transplant atherosclerosis at 24 months;
a second patient died of complications of renal failure–dial-
ysis (with an explanted renal allograft) at 28 months; and a
third patient died of interstitial pneumonitis at 54 months.
Discussion
Although combined heart-kidney transplantation with allo-
grafts from the same donor has been long proved to be a fea-
sible therapeutic option, it is rarely performed. The United
Network for Organ Sharing Registry reports 165 such com-
bined organ transplantations performed between 1988
(when the United Network for Organ Sharing began collect-
ing transplantation data) and 1999. During the same period
of time, 25,952 heart and 126,132 kidney transplantations
were performed in the United States, and combined heart-
kidney transplantation represents 0.6% and 0.1% of the total
heart and kidney transplantation experiences, respectively,
during the same period of time.2 In our institution 286
patients have undergone heart transplantation, and 962
patients have undergone kidney transplantation, whereas
only 10 such combined procedures have been performed. At
present, 1- and 5-year survivals of 82% and 65%, respec-
tively, can be expected for heart transplantation.3 The cur-
rent 1- and 5-year patient survivals for cadaveric kidney
transplantation are 94% and 82%, with expected 1- and 5-
year allograft survivals of 84% and 62%, respectively. Even
higher survival are expected for living-related kidney trans-
plantation.2 This success in single-organ transplantation has
been translated into expanded indications for heart and kid-
ney transplantation.
Since the initial report of simultaneous heart-kidney
transplantation with allografts from the same donor in
1978,4 multiple solid-organ transplantation has evolved into
Figure 1. Actuarial survival for patients having heart-kidney and
heart-only transplantation. NS, Not significant; SE, standard error.
TABLE 1. Preoperative patient characteristics
Age at transplantation (y)
Mean ± SD 59.0 ± 8.3
Range 44-70
Male sex 10 (100%)
Cardiomyopathy
Ischemic 7 (70%)
Idiopathic 3 (30%)
NYHA class
III 3 (30%)
IV 7 (70%)
Diabetes mellitus 5 (50%)
LVEF (%)
Mean ± SD 19.4 ± 5.0
Range 9-25
Creatinine level (mg/dL)
Mean 4.05
Range 2.2-7.1
Creatinine clearance (mL/min)
Mean 25.4
Range 10-39
Previous operations
CABG 5
AVR 1
Transplant status (UNOS)
I 6 (60%)
II 4 (40%)
Waiting time to transplant (d)
Mean ± SD 197 ± 201
Range 14-700
SD, Standard deviation; NYHA, New York Heart Association; LVEF, left ven-
tricular ejection fraction; CABG, coronary artery bypass grafting; AVR, aor-
tic valve replacement; UNOS, United Network for Organ Sharing.
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an acceptable approach with satisfactory short and interme-
diate results. Although the long-term results of combined
heart-kidney transplantation are not known yet, the
observed survival trend matches the rates for heart and kid-
ney transplantation and is associated with a lower incidence
of rejection in both allografts.1,5,12 This decreased rejection
rate is intriguing and occurs despite the fact that heart-kid-
ney transplant patients receive randomly HLA-matched
hearts and kidneys, as do heart-only recipients. Although the
effects of poor or no HLA matching on long-term combined
heart-kidney transplant recipients is uncertain, it appears
that HLA incompatibility is not associated with rejection
but does affect the survival.13 However, other studies have
shown that the number of HLA mismatches predicts not
only the rejection rate but also the mortality rate after heart
transplantation. HLA-B antigen mismatch, and particularly
2 HLA-DR antigen mismatches, are associated with a high-
er rejection rate and a stronger immune response.14,15
Optimal HLA compatibility, particularly HLA-DR, reduces
the strength of the immune response in kidney transplanta-
tion and is associated with a greater long-term patient and
allograft survival.14,16,17 Even though no HLA matching is
performed in heart or combined heart-kidney transplanta-
tion, although it is routinely used in kidney transplantation
in our institution, the low incidence of rejection in our series
of heart-kidney transplantation and in previously published
reports is noteworthy. It has been long observed in experi-
mental animals that multiple transplanted organs from the
same donor protect each other immunologically. This sug-
gests that any organ transplant combination may induce
graft tolerance or reduce host immunoresponsiveness,
although the validity of this immune event in human
patients is not clearly known.18
A second advantage of using allografts from the same
donor is the avoidance of further antigenic stimulation and
immunologic burden because a second unrelated allograft
with different HLA typing might further enhance the recip-
ient’s immune response (ie, living-related kidney donor
because it implies 2 different donors for combined heart-
kidney transplantation).
It has also been observed that the incidence of graft tol-
erance is increased in patients who have received multiple
allogenic transfusion before renal transplantation, perhaps
caused by specific T-cell tolerance.19 Because the quantita-
tive presence of major histocompatibility complex class I
and class II antigens in the kidney is 14- and 18-fold higher
than in the heart, respectively, it is possible that the coexis-
tence of an organ with quantitatively higher but qualitative-
ly similar antigenic determinant may help induce immune
tolerance to the organ with lower antigenic expression.5,20
This is supported by the lower incidence of rejection
observed in other combinations of solid-organ transplanta-
tion, such as heart-lung and kidney-pancreas transplanta-
tion.21,22 It has been suggested that hematopoietic stem cells
from the allograft migrate to the recipient’s bone marrow
and other lymphoid organs. The coexistence of the allograft
cells with the recipient’s precursor stem cells may result in
the development of spontaneous chimerism perpetuated by
the mutual cell engagement of donor and host leukocytes.
Cardiothoracic Transplantation Blanche et al
TABLE 2. Causes of renal disease
Glomerulosclerosis 3
Diabetic nephropathy 2
Renal artery stenosis 2
Tubulointerstitial fibrosis 1
Nephrotic syndrome 1
Intravenous contrast nephropathy 1
TABLE 3. Preoperative renal function and dialysis status
Creatinine level (mg/dL)* Creatinine clearance (mL/min)† Dialysis
7.1 10 +
7.1 0‡ +
5.9 26 +
5 12 +
3.3 35 –
2.9 39 –
2.4 20 –
2.3 36 –
2.3 39 –
2.2 37 –
*At the time of transplantation.
†At the time of listing for transplantation.
‡Patient undergoing dialysis because of a previously unsuccessful kidney
transplantation.
TABLE 4. Donor heart characteristics
Age (y)
Mean ± SD 26.2 ± 13.5
Range 12-54
Male sex 10 (100%)
SD, Standard deviation.
TABLE 5. Intraoperative characteristics allograft ischemic
time
Cardiac (min)
Mean ± SD 170.7 ± 38.2
Range 104-228
Renal (h)
Mean ± SD 23.3 ± 10.7
Range 16-49.5
SD, Standard deviation.
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This interaction may lead to the stimulation of suppressor T
cells, with a mutually inhibitory immune response between
the host and the allograft. This may be further enhanced by
the presence of an immunosuppressive agent, such as
cyclosporine or an anti-CD4 agent, with a resultant
immunotolerance rather than rejection.5,6
In addition to the low incidence of rejection, it has been
noted that simultaneous rejection of cardiac and renal allo-
grafts are rare1,5,6,9 and that the occurrence of rejection in
combined heart-kidney transplantation is independent in
each allograft. Thus, monitoring of rejection must be carried
out separately for each transplanted organ. The observed
incidence, albeit low, of rejection episodes in heart-kidney
transplant patients is slightly higher in the cardiac allograft
than in the renal allograft.5 It is possible, however, that this
may be due in part to the histopathologic need to confirm
the presence of cardiac rejection rather than using the indi-
rect biochemical techniques, Doppler ultrasound diagnostic
techniques, or both, to confirm renal allograft rejection.
Because renal biopsy specimens are rarely performed to
diagnose rejection, perhaps an unknown number of subclin-
ical episodes may be missed, and the conclusion that rejec-
tion does not occur simultaneously in the heart and kidney
allograft may not be valid.
It has been argued that simultaneous, rather than staged,
transplantation of cardiac and renal allografts is preferable
because ischemic allograft injury increases expression of class
I and class II histocompatibility complex antigens in experi-
mental models. A longer ischemic time may render the renal
parenchyma more immunogenic6 and may lead to poorer renal
function with significantly reduced long-term survival.11
Although this was not observed in this series, we believe the
staged approach (ie, implantation of the renal allograft is per-
formed hours later as a separate surgical intervention) has sev-
eral advantages. It allows for hemodynamic stabilization in the
early postoperative period, particularly if hemodialysis was
performed during cardiopulmonary bypass. The avoidance of
right ventricular failure is of paramount importance in the
eventual outcome of the renal allograft. Every attempt should
be made to decrease the amount of inotropic support without
compromising hemodynamics, in particular those agents that
may be deleterious to the renal allograft (ie, α-adrenergic
agents). For those reasons, the use of borderline or high-risk
donors or those with a potential long ischemic cardiac allo-
graft time are avoided. The prompt recovery of cardiac func-
tion is essential to the outcome of the renal allograft. Finally,
the staged approach allows for correction of any coagulation
abnormality that may be present as a result of chronic preop-
erative congestive heart failure. We believe that patients under-
going heart-kidney transplantation should be in optimal hemo-
dynamic and hematologic condition before implantation of the
renal allograft because the loss of the transplanted kidney
would adversely affect their management and long-term
results. In our experience a mean ischemic time of 23.3 hours
was of no detriment to the renal allografts, and diuresis was
observed soon after implantation. However, there is not
enough accumulated experience with combined heart-kidney
transplantation by any single transplant center to claim superi-
ority of one approach over the other.
Finally, given the 1- and 2-year actuarial survival of 76%
and 67%, respectively, of combined heart-kidney transplanta-
tion with an associated actuarial freedom of rejection of 77%
at 1 year in a multi-institutional study,5 the indications for
transplantation in patients with coexisting end-stage heart and
kidney disease have been expanded. This is reinforced by the
satisfactory long-term results and actuarial survival presented
in this study. That is, potential heart transplant candidates
with severe chronic renal dysfunction caused by a fixed and
nonreversible parenchymal disease appear to be good candi-
dates for combined heart-kidney transplantation. Although
there are no established guidelines, it has been suggested that
a glomerular filtration rate of less than 30 mL/min, a serum
creatinine level of more than 2 mg/dL, or both, would be an
indication for such combined organ transplantation.23,24 We
use similar criteria for combined heart-kidney transplantation
in our institution because these values seem to indicate the
increased likelihood of postoperative renal failure, partly
exacerbated by the nephrotoxic effect of immunosuppressive
agents within a year after transplantation. However, because
there is always some component of renal dysfunction in
patients with severe congestive heart failure that may prompt
a worse interpretation of the end-stage nature of the renal dis-
ease in the pretransplant period, a careful interpretation of
these measured renal physiologic parameters is needed to
avoid unnecessary transplantation of a renal allograft in a
patient with potentially recoverable renal function. This
approach is facilitated by the fact that our organ procurement
TABLE 6. Postoperative renal function
Postoperative creatinine
Preoperative creatinine (mg/dL)
level (mg/dL) Preoperative dialysis 1 mo 1 y
7.1 + 1.6 1.2
7.1 + 1.1 0.9
5.9 + 1.6 1.5
5.0 + 1.0 1.1
3.3 – 1.3 1.2
2.9 – 1.6 2.8*
2.4 – 1.4 1.8
2.3 – 1.6 1.8
2.3 – 0.9 1.8
2.2 – 0.9 1.1
*Patient underwent allograft nephrectomy for acute rejection 1 month
after transplantation with partial recovery of native renal junction but
required dialysis 1 year later.
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agencies allow for double-organ transplant listing from a sin-
gle donor. Conversely, potential candidates for renal trans-
plantation with coexisting end-stage heart disease not
amenable to other cardiac operative interventions would be
good candidates for combined heart-kidney transplantation.
It could be debated that this combined approach may not
represent a rational or optimal use of the scarce donor
resources available because 2 donor organs are allocated to a
single individual with double-organ failure rather than 2 allo-
grafts being transplanted into 2 separate patients with single-
organ failure. Although these issues are important, and as
controversial as they may seem, the medical, ethical, and
moral justification of allocation of donor organs goes beyond
the scope of this article. Perhaps these questions can be par-
tially answered by the satisfactory results, including quality
of life, obtained in the patients described in this report.
In summary, on the basis of the good results obtained
with combined heart-kidney transplantation, this approach
has become an effective therapeutic option for a growing
number of patients with coexisting end-stage heart and kid-
ney disease. Intermediate and long-term results are similar
to those of single-organ transplantation, with an observed
low incidence of rejection when both allografts are from the
same donor. Simultaneous rejection of both allografts is
rare, and therefore rejection monitoring and surveillance
should be carried out separately for each transplanted organ.
The low rejection rate observed raises many immunologic
questions and needs further clarification. The criteria for
patient selection now seems well established, and our expe-
rience indicates that the staged approach for allograft
implantation does not adversely affect the renal allograft
and gives satisfactory long-term results. Finally, because of
the limited experience of single centers with combined
heart-kidney transplantation, multicenter studies with a
larger patient population are needed to validate these results.
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